Perforated peptic ulcer: use of pre-admission oral glucocorticoids and 30-day mortality

被引:27
作者
Christensen, S
Riis, A
Norgaard, M
Thomsen, RW
Tonnesen, EM
Larsson, A
Sorensen, HT
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ Hosp, Dept Anesthesiol & Intens Care Med, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ Hosp, Aalborg Hosp, Dept Anesthesiol & Intens Care Med, DK-8000 Aarhus C, Denmark
[4] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA
关键词
D O I
10.1111/j.1365-2036.2006.02722.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Despite evidence that use of glucocorticoids increases the risk of complicated peptic ulcer disease, limited data exist on how use of oral glucocorticoids affects outcome for patients with peptic ulcer perforation. Aim To examine 30-day mortality from peptic ulcer perforation among pre-admission oral glucocorticoid users compared with non-users. Methods We identified 2061 patients with a first-time hospital discharge diagnosis of perforated peptic ulcer, using population-based discharge registries in three Danish counties. Data on use of glucocorticoids and other ulcer-related drugs, previous hospitalizations for uncomplicated peptic ulcer disease, and comorbidity were obtained from discharge registries and prescription databases. Follow-up data on mortality were provided by the Danish Civil Registry System. Results A total of 228 patients (11.1%) were exposed to glucocorticoids within 60 days of admission. Overall 30-day mortality rate was 25.2%, the corresponding rate among current glucocorticoid users was 39.4%. Compared with 'never users', the adjusted mortality ratio among current users of oral glucocorticoids alone was 2.1 (95% CI: 1.5-3.1). Among current users of oral glucocorticoids in combination with other ulcer-related drugs the mortality ratio was 1.5 (950/6 CI: 1.1-2.1). Conclusion Pre-admission use of oral glucocorticoids is associated with up to a twofold increase in 30-day mortality among patients hospitalized with perforated peptic ulcer.
引用
收藏
页码:45 / 52
页数:8
相关论文
共 29 条
[1]  
Andersen TF, 1999, DAN MED BULL, V46, P263
[2]  
BODNER B, 1990, SURG GYNECOL OBSTET, V171, P315
[3]   RISK STRATIFICATION IN PERFORATED DUODENAL-ULCERS - A PROSPECTIVE VALIDATION OF PREDICTIVE FACTORS [J].
BOEY, J ;
CHOI, SKY ;
POON, A ;
ALAGARATNAM, TT .
ANNALS OF SURGERY, 1987, 205 (01) :22-26
[4]   Acute surgical treatment of complicated peptic ulcers with special reference to the elderly [J].
Bulut, O ;
Rasmussen, C ;
Fischer, A .
WORLD JOURNAL OF SURGERY, 1996, 20 (05) :574-577
[5]   Epidemiology of duodenal ulcer perforation: a study on hospital admissions in Norfolk, United Kingdom [J].
Canoy, DS ;
Hart, AR ;
Todd, CJ .
DIGESTIVE AND LIVER DISEASE, 2002, 34 (05) :322-327
[6]   Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database [J].
Cattaruzzi, C ;
Troncon, MG ;
Agostinis, L ;
Rodríguez, LAG .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (06) :499-502
[7]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[8]   NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND PEPTIC-ULCER PERFORATION [J].
COLLIER, DS ;
PAIN, JA .
GUT, 1985, 26 (04) :359-363
[9]  
DAYTON MT, 1987, ARCH SURG-CHICAGO, V122, P376
[10]   How to measure comorbidity: a critical review of available methods [J].
de Groot, V ;
Beckerman, H ;
Lankhorst, GJ ;
Bouter, LM .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (03) :221-229